ZWZhenran Wang

Zhenran Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhenran Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Ruilong Kou

    Department of Gastrointestinal Surgery, Affiliated Hospital of Guilin Medical University, Guilin, China

    1 shared publication
  • Siqi Chen

    Department of Gastrointestinal Surgery, Affiliated Hospital of Guilin Medical University, Guilin, China

    1 shared publication
  • Xiaochen Xu

    Department of Gastrointestinal Surgery, Affiliated Hospital of Guilin Medical University, Guilin, China

    1 shared publication
  • Xinwen Zhang

    Department of Gastrointestinal Surgery, Affiliated Hospital of Guilin Medical University, Guilin, China

    1 shared publication
  • Yihao Liu

    Department of Gastrointestinal Surgery, Affiliated Hospital of Guilin Medical University, Guilin, China

    1 shared publication
  • Zhiyuan Jian

    Department of Gastroenterology Surgery, The First Affliated Hospital of Guilin Medical University, Guilin, Guangxi, China

    1 shared publication

Latest Publications

  • Open Access

    Prognosis and immunotherapy response prediction based on M2 macrophage-related genes in colon cancer

    by Xiaochen Xu, Xinwen Zhang, Ruilong Kou, Yihao Liu, Siqi Chen, Zuguo Li, Zhiyuan Jian, Zhenran Wang

    Background: M2 macrophage were revealed to play a crucial role in immune evasion and immunotherapies. This study aims to explore the potential significance of M2 macrophage-related genes in colon adenocarcinoma (COAD) by analysizing the transcriptome data in a comprehensive way. Methods: We collected RNA-sequencing (RNA-seq) data of COAD from The Cancer Genome Atlas (TCGA) and Gene Expression Ominibus (GEO) databases. We calculated the immune infiltration scores of every sample using CIBERSORT algorithm. Through weighted gene co-expression network analysis (WGCNA), we picked out M2 macrophage-related genes. With these genes we screened out prognosis related genes which were utilized to construct a signature to assess the prognosis of patients. To extend the potential application of the signature, we also calculated the correlations with immune infiltration. Finally, we applied techniques such as quantitative reverse transcription polymerase chain reaction (qRT–PCR) and immunoblotting (Western Blotting) to validate the RNF32 gene in cellular in vitro assays. Results: Seven M2 macrophage-related genes signature was constructed, which was an excellent prognostic predictor in two independent groups. The high-risk group showed lower immune infiltration and poorer response to immunotherapies than those of the low-risk group. The cell vitro experiments showed that the expression level of RNF32 was upregulated in colon cancer cell lines compared with normal cell lines. Moreover, we found that RNF32 may promote the proliferation, migration and invasion of cancer cells in vitro by inhibiting apoptosis. Conclusion: A novel M2 macrophage-related gene signature affects the prognosis and immune characteristics of colon cancer.